maldi-tof mass spectrometry to map disulfide formation in a recombinant human neonatal fc receptor...

23
MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS Functional Genomics in the Nordic Countries 2nd ESF Functional Genomics and Disease – satellite meeting Oslo, 6th September 2005 Jan T Andersen, Inger Sandlie Institute of Molecular Biosciences, UiO Sune Justesen, Søren Buus Institute of Medical Microbiology and Immunology, University of Copenhagen Anders Holm, Burkhard Fleckenstein Institute of Immunology, UiO

Upload: jean-stafford

Post on 16-Jan-2016

215 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro

Study of protein conformation by MS

Functional Genomics in the Nordic Countries2nd ESF Functional Genomics and Disease – satellite meeting

Oslo, 6th September 2005

Jan T Andersen, Inger SandlieInstitute of Molecular Biosciences, UiO

Sune Justesen, Søren Buus Institute of Medical Microbiology and Immunology, University of Copenhagen

Anders Holm, Burkhard FleckensteinInstitute of Immunology, UiO

Page 2: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor, by Anthony P. West, Jr. and Pamela J. Bjorkman (2000) Biochemistry 39, 9698 - 9708

The neonatal Fc receptor (FcRn) is a MHC class I related glycoprotein

Unlike MHC class I, FcRn is nonpolymorphic and lacks a functional peptide binding groove

β2-microglobulin is essential for FcRn function

Structure of the heterodimeric FcRn

N

C48 C251C96 C159 C198 C252

C

α1-domain α2-domain α3-domain TM CP

Page 3: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Functions of the human neonatal Fc receptor

Multiple roles for the major histocompatibility complex class I- related receptor FcRn.by Ghetie V, Ward ES (2000) Annu Rev Immunol 18, 739-66. Review. Immunoglobulin transport across polarized epithelial cells.by Rojas R, Apodaca G (2002) Nat Rev Mol Cell Biol 3, 944-55. Review.

Regulation of the IgG-biodistribution. IgG recycling and/or degradation in endothelial cells. Binding to the Fc portion of IgG within acidic intracellular compartments (pH 6.0). Release of IgG upon exposure to the slightly basic extracellular environment (pH 7.4) Birectional epithelial transport of IgG/IgG-Ag over mucosal surfaces. Transplacental transport of IgG from mother to fetus (passive immunization).

Page 4: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Major objectives of the study

Establish a protocol to generate large amounts of soluble, functional

recombinant shFcRn

Characterize the folding of the shFcRn heavy chain by

mass spectrometry

Page 5: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

The FcRn heavy chain is functional when expressed as a soluble truncated form in eukaryotic cells.

Eukaryotic expression gives low yield at a high cost. Bacteria, however, lack the folding machinery available in eukaryotic cells.

MHC class I has been expressed in E. coli and refolded from inclusion bodies in vitro:

Refolding of correctly oxidized MHC class I heavy chains to the native structure in the presence of 2m (Ferre et al., 2003, Protein Sci. 12, 551-9)

Expression, extraction and in vitro refolding are affected by the number of cysteine residues in the recombinant protein.

Background

Page 6: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Soluble wild-type (wt):15 possible SS bonds

Soluble double mutant (mut):6 possible SS bonds

1 possible disulfide bond2m

C48 C251C96 C159 C198 C252

HAT

C48S C251SC96 C159 C198 C252

HAT

C25 C80

HAT

N

C48 C251C96 C159 C198 C252

C

α1-domain α2-domain α3-domain TM CP

wild-type (wt)

Constructs and possible disulfide bonds within the hFcRn heavy chain and h2m

Page 7: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Heterologous expression of soluble hFcRn heavy chain and 2m in E. coli and disulfide assisted oxidative refolding

0 1 2 3 hours

hFcRnheavy chainmutant

1) EXPRESSION IN INCLUSION BODIES IPTG induction

IMAC, HIC and SEC purification

all steps performed under denaturing but non-reducing conditions

gram levels of hFcRn heavy chain (wt and mut)

Purified denatured shFcRn heavy chains were diluted into a solution with an excess of β2m.

hFcRn heavy chains fold up on 2m.

Purification of folded heterodimers by SEC.

Non-reducing SDS-PAGE.Eluted fractions from SEC purification of shFcRn (C48S/C251S).

Heterodimeric fraction

F: 38-54 55-67 74-84

shFcRn (WT): 2.6 mg shFcRn (C48S/C251S): 22.2 mg

2) REFOLDING

The correct folding of hFcRn is dependent on the presence of 2m.

Page 8: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

MALDI-TOF mass spectrometry to map disulfide formation in

a recombinant human neonatal Fc receptor refolded in vitro

Does in vitro refolding in the presence of 2m select the correctly folded heavy chains?

Ultraflex, MALDI-TOF

Bruker Daltonics

Page 9: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Major questions addressed by MALDI-TOF MS

Presence and completeness of the expected (correct) disulfide bonds?

Presence of wrong disulfide bonds?

Presence of free cysteine residues – expected vs unexpected?

Strategy (I)

Separation of refolded 2m - hFcRn heavy chain heterodimers on a

denaturing but non-reducing gel Excision of the Coomassie-stained bands Alkylation of free cysteine residues with iodoacetamide in gel digestion with trypsin

Detection of intact disulfide bonded peptides

Page 10: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

The expected disulfide bond in 2m is proven

No signals corresponding to free cysteine residues were found in 2m.

SNFLNCYVSGFHPSDIEVDLLK DEYACRC25 C80

MH+ 3250.5 SNFLNCYVSGFHPSDIEVDLLK DEYACRC25 C80

SNFLNCYVSGFHPSDIEVDLLK DEYACRC25 C80

MH+ 3250.5

1122.642

1946.963

1674.814

1475.802

3250.504

2497.208

1010.3422203.043

2780.348

844.7632940.311

1854.911

3348.631

1383.725 2318.1192681.198

3052.616

00101-00200\00188bf\1SRef

0

2000

4000

6000

8000

Inte

ns.

[a.u

.]

750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250

m/z

3250.504

0

1000

2000

3000

4000

5000

6000

Inte

ns.

[a.u

.]

3245 3250 3255 3260

m/z

C25 C80

HAT

Page 11: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Both correct disulfide bonds were observed in the mut-hFcRn

1SRef

0

10

20

30

40

50

60

Inte

ns. [a

.u.]

5176.453 2SRef

500

1000

1500

2000

2500

3000

Inte

ns. [a

.u.]

5173.601 3SRef

1000

2000

3000

4000

Inte

ns. [a

.u.]

1SLin Raw

0.2

0.4

0.6

0.8

1.0

4x10

Inte

ns. [a

.u.]

5000 5100 5200 5300 5400

m/z

5176.42

Linear Modeexp. MH+ 5175.82No signals corresponding to wrong

disulfide bonds were detected.

3891.453

1SRef

500

1000

1500

2000

2500

Inte

ns. [a

.u.]

3891.098

2SRef

0

1000

2000

3000

4000

5000

Inte

ns. [a

.u.]

3891.1183SRef

0

1000

2000

3000

4000

Inte

ns. [a

.u.]

3880 3885 3890 3895 3900 3905 3910

m/z

1SRef

0

10

20

30

40

50

60

Intens. [a.u.]

5176.453 2SRef

500

1000

1500

2000

2500

3000

Intens. [a.u.]

5173.601 3SRef

1000

2000

3000

4000

Intens. [a.u.]

1SLin Raw

0.4

0.6

0.8

1.0

4x10

Intens. [a.u.]

5165 5170 5175 5180 5185 5190

m/z

exp. MH+ 3890.95 exp. MH+ 5172.52

ARPSSPGFSVLTCSAFSFYPPELQLR

SGDEHHYSCIVQHAGLAQPLR

C198

C252

C48S C251SC96 C159 C198 C252

HAT

GPYTLQGLLGCELGPDNTSVPTAK

ELTFLLFSCPHR

C96

C159

Page 12: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Strategy (II)

Alkylation of free cysteine residues with iodoacetamide Reduction by DTT and alkylation by iodoacetic acid in gel digestion with trypsin

Detection of free cysteine residues which are alkylated by -CH2-CONH2

Detection of cysteine residues participating in disulfide formation

which are alkylated by –CH2-COOH

GPYTLQGLLGCELGPDNTSVPTAKC96

CH2-CONH2

GPYTLQGLLGCELGPDNTSVPTAKC96

CH2-CONH2

GPYTLQGLLGCELGPDNTSVPTAKC96

CH2-COOH

GPYTLQGLLGCELGPDNTSVPTAKC96

CH2-COOH

MH+ 2488.2 MH+ 2489.2m = + 1 Da

How complete is the formation of a disulfide bond?

Page 13: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

C96-peptide-CH2-COOH:exp. MH+ 2489.24

C159-peptide-CH2-COOH:exp. MH+ 1520.77

2489.321

0

2000

4000

6000

Inte

ns. [a

.u.]

2489.334 2SRef

0

1000

2000

3000

Inte

ns. [a

.u.]

2470 2475 2480 2485 2490 2495 2500 2505

m/z

2489.33

1519.81

1520.796

0

1

2

3

4x10

Inte

ns. [

a.u.

]

1520.813 2SRef

0.0

0.5

1.0

1.5

4x10

Inte

ns. [

a.u.

]

1510.0 1515.0 1520.0 1525.0 1530.0

m/z

1520.81

Formation of the first disulfide bond in mut-hFcRn is not fully complete

free Cys

1. Disulfide bondSS bonded Cys

GPYTLQGLLGCELGPDNTSVPTAK

ELTFLLFSCPHR

C96

C159

C198-peptide-CH2-COOH:theoret. MH+ 2915.46

C252-peptide-CH2-COOH:theoret. MH+ 2376.13

2376.181

0.00

0.25

0.50

0.75

1.00

1.25

4x10

Inte

ns. [

a.u.

]2376.202 2SRef

0

2000

4000

6000

8000

Inte

ns. [

a.u.

]

2360 2365 2370 2375 2380 2385 2390

m/z

2376.20

2915.622

0

2000

4000

6000Inte

ns. [

a.u.

]

2915.630 2SRef

0

1000

2000

3000

Inte

ns. [

a.u.

]

2910 2915 2920 2925 2930 2935

m/z

2915.63

Complete disulfide bond

formation

2. Disulfide bondARPSSPGFSVLTCSAFSFYPPELQLR

SGDEHHYSCIVQHAGLAQPLR

C198

C252

Page 14: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

A pronounced and unexpected disulfide bond between the vicinal C251 and C252 was found in the wt-hFcRn

1459.733 1691.811

1871.939

2332.099

2780.301

954.155

1342.776

2166.100

2674.2811249.687

1112.6663891.121

2053.025 3196.5852914.5153574.918

00498ns\0_D7\1\1SRef

0

1

2

3

4

5

4x10

Inte

ns.

[a.u

.]

1000 1500 2000 2500 3000 3500

m/z

α1 α2 α3

C48 C251C96 C159 C198 C252

HAT

Page 15: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

The vicinal disulfide bond (C251-C252) was confirmedby MALDI-TOF/TOF-MS

110.178

663.321

2073.108

526.270

962.502

368.264

826.133

175.160754.418301.155

1943.906

1115.485

1806.9411370.548 1507.7232175.996

895.412 1669.835

2315.859

436.169

765.298

1043.880

b68059sa\0_H10\0\2332.1000.LIFT\fast

0.0

0.5

1.0

1.5

2.0

2.5

4x10

Inte

ns. [a

.u.]

250 500 750 1000 1250 1500 1750 2000 2250

m/z

y1

y3

y18

MH+

y19

y17

y16y15

y14

y13:missing !

y12y11y10

y9y8

y7

y6y5

110.178

663.321

2073.108

526.270

962.502

368.264

826.133

175.160754.418301.155

1943.906

1115.485

1806.9411370.548 1507.7232175.996

895.412 1669.835

2315.859

436.169

765.298

1043.880

b68059sa\0_H10\0\2332.1000.LIFT\fast

0.0

0.5

1.0

1.5

2.0

2.5

4x10

Inte

ns. [a

.u.]

250 500 750 1000 1250 1500 1750 2000 2250

m/z

y1

y3

y18

MH+

y19

y17

y16y15

y14

y13:missing !

y12y11y10

y9y8

y7

y6y5

S G D E H H Y C C I V Q H A G L A Q P L R

y-fragments 1356810 791112141516171819

missing

S G D E H H Y C C I V Q H A G L A Q P L RS G D E H H Y C C I V Q H A G L A Q P L R

y-fragments 1356810 791112141516171819

missing

y-fragments 1356810 791112141516171819

missingmissing

S G D E H H Y C C I V Q H A G L A Q P L Ry-fragments 1356810 791112141516171819

missing

S G D E H H Y C C I V Q H A G L A Q P L RS G D E H H Y C C I V Q H A G L A Q P L Ry-fragments 1356810 791112141516171819

missing

y-fragments 1356810 791112141516171819

missingmissing110.178

663.321

2073.108

526.270

962.502

368.264

826.133

175.160754.418301.155

1943.906

1115.485

1806.9411370.548 1507.7232175.996

895.412 1669.835

2315.859

436.169

765.298

1043.880

b68059sa\0_H10\0\2332.1000.LIFT\fast

0.0

0.5

1.0

1.5

2.0

2.5

4x10

Inte

ns. [a

.u.]

250 500 750 1000 1250 1500 1750 2000 2250

m/z

y1

y3

y18

MH+

y19

y17

y16y15

y14

y13:missing !

y12y11y10

y9y8

y7

y6y5

110.178

663.321

2073.108

526.270

962.502

368.264

826.133

175.160754.418301.155

1943.906

1115.485

1806.9411370.548 1507.7232175.996

895.412 1669.835

2315.859

436.169

765.298

1043.880

b68059sa\0_H10\0\2332.1000.LIFT\fast

0.0

0.5

1.0

1.5

2.0

2.5

4x10

Inte

ns. [a

.u.]

250 500 750 1000 1250 1500 1750 2000 2250

m/z

y1

y3

y18

MH+

y19

y17

y16y15

y14

y13:missing !

y12y11y10

y9y8

y7

y6y5

S G D E H H Y C C I V Q H A G L A Q P L R

y-fragments 1356810 791112141516171819

missing

S G D E H H Y C C I V Q H A G L A Q P L RS G D E H H Y C C I V Q H A G L A Q P L R

y-fragments 1356810 791112141516171819

missing

y-fragments 1356810 791112141516171819

missingmissing

S G D E H H Y C C I V Q H A G L A Q P L Ry-fragments 1356810 791112141516171819

missing

S G D E H H Y C C I V Q H A G L A Q P L RS G D E H H Y C C I V Q H A G L A Q P L Ry-fragments 1356810 791112141516171819

missing

y-fragments 1356810 791112141516171819

missingmissing

S G D E H H Y C C I V Q H A G L A Q P L RS G D E H H Y C C I V Q H A G L A Q P L Ry-fragments 1356810 791112141516171819

missing

y-fragments 1356810 791112141516171819

missing

S G D E H H Y C C I V Q H A G L A Q P L RS G D E H H Y C C I V Q H A G L A Q P L Ry-fragments 1356810 791112141516171819

missingmissing

y-fragments 1356810 791112141516171819

missingmissing

Recorded on a Ultraflex MALDI-TOF/TOF-instrument (Bruker) in the laboratory of Peter Roepstorff,

Odense, Denmark

Page 16: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Summary

In 2m and mut-hFcRn -chain, the correct disulfide bonds were demonstrated. In mut-hFcRn heavy chain the formation of the first disulfide bond is almost but not fully

complete. The second disulfide bond formation is complete.

Wrong disulfide bonds were not detected.

C48S C251SC96 C159 C198 C252

HAT

In wt-hFcRn -chain, only the first (correct) disulfide bond was observed.

Small signals corresponding to wrong disulfide bonds as well as unexpected free cysteine

residues were obtained. A pronounced and wrong disulfide bond formation between the vicinal C251 and C252 was

demonstrated by MALDI-TOF/TOF analysis.

C48 C251C96 C159 C198 C252

HAT

Page 17: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Outlook

In the future, disulfide formation in soluble hFcRn expressed both in the prokaryotic and eukaryotic system will be analyzed.

nanoLC-offline-MALDI-TOF will be used to increase the “coverage of conformation” (qualitative approach).

HAT

Iodomethyl-Fluorophore 1

HAT

DTTIodomethyl-Fluorophore 2

HAT

digestion

Quantification and identification byHPLC-fluorescence detection-MS

More quantitative studies on the disulfide formation in hFcRn will be performed.

Use of two fluorescence dyes to differentially label free and disulfide forming cysteines:

Page 18: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS
Page 19: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Characterization of the shFcRn (wt and mut) by Circular Dicroism and Surface Plasmon Resonance

IgG1 was immobilized on a CM5 chip

shFcRn (C48S/C251S) was injected in different concentrations.

Binding of shFcRn (C48S/C251S) to IgG1 at pH6.0

CD spectra show 52.6% and 46.0% (wt and mut, respectively) -sheet structures,14.5% α-helical contribution (for wt and mut)

The functionality of the shFcRn was confirmed by SPR (Biacore):- concentration dependent binding to its ligands: human IgG1, human IgG3 and HSA.- pH dependent binding to ligands: binding at pH 6.0 and no binding pH 7.4.

The bacterially expressed and in vitro refolded shFcRn is functional

RU

time

Page 20: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS
Page 21: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Functions of the human neonatal Fc receptor

Multiple roles for the major histocompatibility complex class I- related receptor FcRn.by Ghetie V, Ward ES (2000) Annu Rev Immunol 18, 739-66. Review. Immunoglobulin transport across polarized epithelial cells.by Rojas R, Apodaca G (2002) Nat Rev Mol Cell Biol 3, 944-55. Review.

Maintenance of IgG- and HSA-homeostasis. Modulation of IgG-biodistribution by recycling

and/or degradation in endothelial cells. Birectional epithelial transport of IgG/IgG-Ag over mucosal surfaces. Transplacental transport of IgG from mother to fetus (passive immunization). Binding to the Fc portion of IgG within acidic intracellular compartments (pH 6.0). Release of IgG upon exposure to the slightly basic extracellular environment (pH 7.4) The interactions are mediated by histidine residues.

Page 22: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

The FcRn heavy chain is functional when expressed as a soluble truncated form in eukaryotic cells.

Eukaryotic expression gives low yield at a high cost. Bacteria, however, lack the folding machinery available in eukaryotic cells.

Expression, extraction and in vitro refolding are affected by the number of cysteine residues in the recombinant protein.

MHC class I has been expressed in E. coli and refolded from inclusion bodies in vitro:Ferre et al. (2003) Protein Sci. 12, 551-9: Purification of correctly oxidized MHC class I heavy-chain molecules under denaturing conditions: a novel strategy exploiting disulfide assisted protein folding

Strategy: disulfide assisted oxidative refolding of the heavy chain in vitro.Refolding of correctly oxidized MHC class I heavy chains to the native structure in the presence of 2m.

Background

Page 23: MALDI-TOF mass spectrometry to map disulfide formation in a recombinant human neonatal Fc receptor refolded in vitro Study of protein conformation by MS

Heterologous expression of soluble hFcRn heavy chain and 2m in E. coli and disulfide assisted oxidative refolding

0 1 2 3 hours

hFcRnheavy chainmutant

Transformation of BL21 (DE3) E. coli

Large scale fermentations (2 L)

Induction of expression by IPTG

IMAC, HIC and SEC purification

gram levels of hFcRn heavy chain wt and mut.

The correct refolding to the native structure is dependent on the presence of 2m.

Purified shFcRn heavy chains (denatured but oxidized) were diluted into a solution with an excess amount of hβ2m.

hFcRn heavy chains fold up on h2m.

Purification of folded heterodimers by SEC.

SDS-PAGE. Eluted fractions from SEC purification of shFcRn (C48S/C251S).

Heterodimeric fraction

F: 38-54 55-67 74-84

shFcRn (WT): 2.6 mg shFcRn (C48S/C251S): 22.2 mg